Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $9.57 and last traded at $9.5360, with a volume of 425442 shares trading hands. The stock had previously closed at $9.27.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 1st. Citigroup decreased their target price on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, March 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 price target on shares of Candel Therapeutics in a research report on Friday, March 13th. Cantor Fitzgerald began coverage on Candel Therapeutics in a research report on Monday, April 20th. They set an “overweight” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a report on Monday, April 20th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Candel Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.
Read Our Latest Stock Report on Candel Therapeutics
Candel Therapeutics Trading Up 1.2%
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.16. Equities analysts expect that Candel Therapeutics, Inc. will post -0.97 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Candel Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its stake in shares of Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after purchasing an additional 4,439 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Candel Therapeutics during the 4th quarter worth $51,000. Tower Research Capital LLC TRC raised its stake in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after purchasing an additional 7,527 shares during the last quarter. Invesco Ltd. acquired a new stake in Candel Therapeutics during the first quarter worth $59,000. Finally, ProShare Advisors LLC bought a new stake in Candel Therapeutics in the 4th quarter valued at $59,000. Institutional investors and hedge funds own 13.93% of the company’s stock.
About Candel Therapeutics
Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.
Read More
- Five stocks we like better than Candel Therapeutics
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
- Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
